COMP <GO>
BTTC vs CLDI // EV/EBITDA & P/E VALUATION
Black Titan Corporation (NASDAQ) VS. Calidi Biotherapeutics Inc. (NYSE) • 15-METRIC TALLY: BTTC 2
— CLDI 1
■ METRIC PARITY
LAST: $0.32 (-8.05%) • MKT CAP: $4.8M
valuation
—
LAST: $0.69 (+2.43%) • MKT CAP: $2.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BTTC VS. CLDI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BTTC | CLDI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.73% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | CLDI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.0 | 30.3 | +7.70 | BTTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.8M | $2.5M | $2.3M | BTTC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BTTC REV | CLDI REV | BTTC GROSS % | CLDI GROSS % | BTTC FCF | CLDI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $869.2K | $56.7M | — | — | -$143.2K | -$21.3M |
| FY 2024 | — | $61.0M | — | — | — | -$19.7M |
| FY 2023 | — | $81.2M | — | — | — | -$27.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BTTC // BETA —
CLDI // BETA —